Details of the Drug
General Information of Drug (ID: DMIZVA6)
Drug Name |
LEUCETTAMINE A
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Leucettamol A; Leucettamine A (lipid); 151124-32-2; AC1O5ZHI; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R*,3S*,5Z,8Z,11Z,14Z,20Z,28S*,29R*)-(+-)-; 334010-39-8; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R*,3S*,5Z,8Z,11Z,14Z,20Z,28S*,29R*)-; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R,3S,5Z,8Z,11Z,14Z,20Z,28S,29R)-rel-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 365.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||